Display options
Share it on

P T. 2016 Mar;41(3):164-72.

Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults.

P & T : a peer-reviewed journal for formulary management

Matthew M Sherman, Sinziana Ungureanu, Jose A Rey

PMID: 26957883 PMCID: PMC4771085

Abstract

Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults.

References

  1. Obesity (Silver Spring). 2009 Jan;17(1):30-9 - PubMed
  2. J Neurosci. 2011 Jan 5;31(1):281-8 - PubMed
  3. Lancet. 2010 Aug 21;376(9741):595-605 - PubMed
  4. Neuroendocrinology. 1990 Nov;52(5):441-7 - PubMed
  5. Clin Pharmacol Ther. 2005 Jun;77(6):553-9 - PubMed
  6. ACS Chem Neurosci. 2011 Sep 21;2(9):484-6 - PubMed
  7. J Neurosci. 1984 Apr;4(4):956-65 - PubMed
  8. Peptides. 2005 Oct;26(10):1800-13 - PubMed
  9. Health Aff (Millwood). 2009 Sep-Oct;28(5):w822-31 - PubMed
  10. Obesity (Silver Spring). 2011 Jan;19(1):110-20 - PubMed
  11. Endocr Rev. 2006 Dec;27(7):736-49 - PubMed
  12. Diabetes Care. 2013 Dec;36(12):4022-9 - PubMed
  13. Obesity (Silver Spring). 2013 May;21(5):935-43 - PubMed
  14. J Clin Pharmacol. 2003 May;43(5):443-69 - PubMed
  15. Obesity (Silver Spring). 2013 May;21(5):893-9 - PubMed
  16. Expert Opin Pharmacother. 2011 Aug;12(11):1813-26 - PubMed
  17. JAMA. 2014 Feb 26;311(8):806-14 - PubMed
  18. Anesthesiology. 2004 Dec;101(6):1487-8 - PubMed
  19. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2985-3023 - PubMed
  20. Pharmacol Res. 2014 Jun;84:1-11 - PubMed

Publication Types